New data from Eli Lilly reveal that 63.5% of ulcerative colitis patients treated with Omvoh maintained disease clearance after four years of continuous treatment. Disease clearance means simultaneous symptom relief, and endoscopic and histologic remission, a high clinical standard linked to fewer hospitalizations and surgeries. This is the first IL-23p19 inhibitor to demonstrate such long-term durable remission, potentially changing the disease's long-term course. Eli Lilly is also exploring combination therapies and pediatric trials to further improve outcomes.
Eli Lilly announced acquisitions of Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc., investing up to $3.8 billion to enhance its infectious disease research and vaccine development. These deals align with Lilly's strategy to prevent di...
Eli Lilly announced it will acquire three vaccine developers—Curevo, LimmaTech Biologics AG, and Vaccine Company—in deals totaling up to $3.83 billion. This strategic move expands Lilly's focus into infectious disease prevention, complementing its ex...
Lilly has agreed to acquire Curevo Vaccine, a biotech firm developing a next-generation shingles vaccine called amezosvatein, designed to improve tolerability and increase vaccination rates. The deal could pay Curevo shareholders up to $1.5 billion, ...
Eli Lilly announced plans to acquire Curevo, LimmaTech Biologics, and Vaccine Company for a total of nearly $4 billion in cash. This move aims to expand Eli Lilly's research and development efforts into infectious diseases, focusing on preventing dis...
Eli Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company to expand its infectious disease research. These acquisitions focus on developing vaccines targeting viral and bacterial pathogens linked to long-term health r...
